BACKGROUND: Various drugs have been tried to hasten cervical dilatation so that problems and hazards of prolonged labour both for the mother and fetus are minimised without increasing maternal or perinatal mortality and morbidity. AIMS AND OBJECTIVES: To compare the effect of camylofin dihydrochloride with combination of valethemate bromide (epidosin) & hyoscine N butyl bromide (buscopan) on cervical dilatation, evaluate the incidence of side effects and to look for neonatal outcome. MATERIAL AND METHODS: Two hundred cases were included of primigravidae or multigravidae with gestational age of 37 to 40 weeks with full term with single foetus,vertex presentation and no major antenatal complication of women in labour, admitted to labour room of gynaecology Department, Government Medical College, Patiala, India, was studied and divided into 2 groups Group A-100 Cases - labour accelerated by camylofin dihydro chloride and Group B-100 Cases-labour accelerated by valethemate bromide (epidosin) and hyoscine N butyl bromide. OBSERVATIONS: The mean age, parity and period of gestation in Anafortan group was 24.13 ± 3.60 years, 49% primigravidae and 51% multigravidae and 38.81 ± 1.09 weeks, while that in Epidosin + Buscopan group was 24.43 ± 3.42 years, 45% primigravidae and 51% multigravidae and 38.94 ± 1.09 weeks respectively. The difference was insignificant and both the groups were comparable. RESULTS: Mean duration of Active phase of 1st stage of labor was 141.40 ± 55.41 minutes in Anafortan group and 181.46 ± 75.58 minutes in Epidosin + Buscopan group. Mean rate of cervical dilatation according to active phase of first stage was 3.33 ± 1.03 cm/hours in Anafortan group and 2.69 ± 1.03 cm/hr in Epidosin + Buscopan group. The difference between the two groups is highly significant (p < 0.01) thus it is concluded that Anafortan hastened the rate of cervical dilatation.
BACKGROUND: Various drugs have been tried to hasten cervical dilatation so that problems and hazards of prolonged labour both for the mother and fetus are minimised without increasing maternal or perinatal mortality and morbidity. AIMS AND OBJECTIVES: To compare the effect of camylofin dihydrochloride with combination of valethemate bromide (epidosin) & hyoscine N butyl bromide (buscopan) on cervical dilatation, evaluate the incidence of side effects and to look for neonatal outcome. MATERIAL AND METHODS: Two hundred cases were included of primigravidae or multigravidae with gestational age of 37 to 40 weeks with full term with single foetus,vertex presentation and no major antenatal complication of women in labour, admitted to labour room of gynaecology Department, Government Medical College, Patiala, India, was studied and divided into 2 groups Group A-100 Cases - labour accelerated by camylofin dihydro chloride and Group B-100 Cases-labour accelerated by valethemate bromide (epidosin) and hyoscine N butyl bromide. OBSERVATIONS: The mean age, parity and period of gestation in Anafortan group was 24.13 ± 3.60 years, 49% primigravidae and 51% multigravidae and 38.81 ± 1.09 weeks, while that in Epidosin + Buscopan group was 24.43 ± 3.42 years, 45% primigravidae and 51% multigravidae and 38.94 ± 1.09 weeks respectively. The difference was insignificant and both the groups were comparable. RESULTS: Mean duration of Active phase of 1st stage of labor was 141.40 ± 55.41 minutes in Anafortan group and 181.46 ± 75.58 minutes in Epidosin + Buscopan group. Mean rate of cervical dilatation according to active phase of first stage was 3.33 ± 1.03 cm/hours in Anafortan group and 2.69 ± 1.03 cm/hr in Epidosin + Buscopan group. The difference between the two groups is highly significant (p < 0.01) thus it is concluded that Anafortan hastened the rate of cervical dilatation.
Entities:
Keywords:
Anafortan; Buscopan; Cervical dilatation; Epidosin; labour
Authors: Aaron B Caughey; Vandana Sundaram; Anjali J Kaimal; Yvonne W Cheng; Allison Gienger; Sarah E Little; Jason F Lee; Luchin Wong; Brian L Shaffer; Susan H Tran; Amy Padula; Kathryn M McDonald; Elisa F Long; Douglas K Owens; Dena M Bravata Journal: Evid Rep Technol Assess (Full Rep) Date: 2009-03